ArticleJournal of cellular and molecular medicine2018

The FDA approved PI3K inhibitor GDC-0941 enhances in vitro the anti-neoplastic efficacy of Axitinib against c-myc-amplified high-risk medulloblastoma.

Michael Ehrhardt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.